Cargando…
Exploring the Frequency of Homologous Recombination DNA Repair Dysfunction in Multiple Cancer Types
Dysfunctional homologous recombination DNA repair (HRR), frequently due to BRCA mutations, is a determinant of sensitivity to platinum chemotherapy and poly(ADP-ribose) polymerase inhibitors (PARPi). In cultures of ovarian cancer cells, we have previously shown that HRR function, based upon RAD51 fo...
Autores principales: | Gentles, Lucy, Goranov, Bojidar, Matheson, Elizabeth, Herriott, Ashleigh, Kaufmann, Angelika, Hall, Sally, Mukhopadhyay, Asima, Drew, Yvette, Curtin, Nicola J., O’Donnell, Rachel L |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6468835/ https://www.ncbi.nlm.nih.gov/pubmed/30871186 http://dx.doi.org/10.3390/cancers11030354 |
Ejemplares similares
-
Assessing the function of homologous recombination DNA repair in malignant pleural effusion (MPE) samples
por: Patterson, M J, et al.
Publicado: (2014) -
Genomic, Transcriptomic, and Functional Alterations in DNA Damage Response Pathways as Putative Biomarkers of Chemotherapy Response in Ovarian Cancer
por: Sharma Saha, Sweta, et al.
Publicado: (2021) -
Characterization and drug sensitivity of a novel human ovarian clear cell carcinoma cell line genomically and phenotypically similar to the original tumor
por: Franklin, Miriam, et al.
Publicado: (2018) -
Differences in Durability of PARP Inhibition by Clinically Approved PARP Inhibitors: Implications for Combinations and Scheduling
por: Smith, Hannah L., et al.
Publicado: (2022) -
Characterisation of Ovarian Cancer Cell Line NIH-OVCAR3 and Implications of Genomic, Transcriptomic, Proteomic and Functional DNA Damage Response Biomarkers for Therapeutic Targeting
por: Bradbury, Alice, et al.
Publicado: (2020)